Aerie ROCKETS On Glaucoma Data
This article was originally published in Scrip
Executive Summary
Aerie Pharmaceuticals Inc. has reported positive results from its second Phase III trial for Rhopressa (AR-13324), which is being tested to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The news sent the company's share price soaring by almost 70% (Sep. 17), and Aerie expects to file its NDA for Rhopressa in mid-2016.
You may also be interested in...
Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
Positive Phase III data for Aerie's second glaucoma drug candidate Roclatan – which will support a US FDA submission in the first half of 2018 – have boosted the California company's M&A allure.
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC
The latest drug development news and highlights from our FDA Performance Tracker.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.